LLY vs NVS
LLY: A global pharmaceutical powerhouse developing innovative medicines across cardiometabolic, oncology, and immunology with blockbuster GLP-1 and weight-loss franchises driving exceptional growth. NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
Side-by-side fundamentals
| Metric | LLY | NVS | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $1,148.84 | $156.11 | |
| Market cap as of 2026-08-03 | $1.08T | $232.1B | |
| P/E as of 2026-08-03 | 40.81 | 22.53 | NVS lower |
| PEG as of 2026-08-03 | 1.48 | 3.66 | LLY lower |
| Net margin as of 2026-08-03 | +35.0% | +22.5% | LLY higher |
| Gross margin as of 2026-08-03 | +82.8% | +75.0% | LLY higher |
| Operating margin as of 2026-08-03 | +43.6% | +29.9% | LLY higher |
| ROE as of 2026-08-03 | +101.3% | +29.9% | LLY higher |
| ROA as of 2026-08-03 | +22.7% | +11.1% | LLY higher |
| Debt / equity as of 2026-08-03 | 1.39 | 1.18 | NVS lower |
| Revenue growth (YoY) as of 2026-08-03 | +47.4% | +3.3% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | +31.7% | n/a | |
| Dividend yield as of 2026-08-03 | +0.6% | +2.9% | NVS higher |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-03 | 0.63 | 1.17 | |
| 1-year return as of 2026-07-31 close | +55.2% | +32.6% | LLY higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.